Figure 4. Comparisons of primary outcomes between studies using gemcitabine-containing regimens as first-line and second-line treatment.

(A) Overall survival (first-line), (B) Overall survival (second-line) (C) Progression free survival (first-line), (D) Progression free survival (second-line), (E) Objective tumor response rate (first-line), (F) Objective tumor response rate (second-line).